Medicare Price Negotiation “Not A Priority” For House Dems
This article was originally published in The Pink Sheet Daily
Executive Summary
Medicaid rebate increase and follow-on biologics could take $70 billion from pharma over 10 years, key staffer says—but industry should be happy with that trade.
You may also be interested in...
Politics Of Mega-Mergers: Health Reform And U.S. Biopharma Realignment
One theme tying together the two mega-mergers announced so far in 2009 is the sense that biopharma companies are taking defensive measures to prepare for health care reform in the U.S
Politics Of Mega-Mergers: Health Reform And U.S. Biopharma Realignment
One theme tying together the two mega-mergers announced so far in 2009 is the sense that biopharma companies are taking defensive measures to prepare for health care reform in the U.S
The Politics Of Mega-Mergers: Health Care Reform And U.S. Biopharma Realignment
Merck/Schering, Pfizer/Wyeth underscore sense of long-term structural change in U.S. pharma market.